Your email has been successfully added to our mailing list.

×
0.0087912087912088 0.0087912087912088 0.0087912087912088 0.0087912087912088 0.0087912087912088 0.0087912087912088 0.020879120879121 0.0725274725274725
Stock impact report

Protagonist Therapeutics Initiates Phase 1 Study with Novel Hepcidin Mimetic, PTG-300

Protagonist Therapeutics, Inc. (PTGX) 
Last protagonist therapeutics, inc. earnings: 3/10 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.protagonist-inc.com
Company Research Source: PR Newswire
NEWARK, Calif., May 25, 2017 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today announced that the company has initiated a Phase 1 clinical study of PTG-300 in normal healthy volunteers.  PTG-300 is an injectable hepcidin mimetic peptide discovered using the company's proprietary technology platform, and it is being developed as a potential treatment for patients with chronic iron overload in rare diseases such as beta-thalassemia. Hepcidin is a principal regulator of iron homeostasis in humans, and low levels of hepcidin may be associated with iron overload-related diseases such as thalassemia, myelodysplastic syndrome, and hereditary hemochromatosis. Iron overload can damage target organs and tissues including the bone marrow, liver, and heart leading to increased risks of anemia, liver disease, heart attack, heart failure, diabetes, and premature death. Beta-thalassemia is a rare, inherited blood disorder characterized by an underproduction o Show less Read more
Impact Snapshot
Event Time:
PTGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for PTGX alerts
Opt-in for
PTGX alerts

from News Quantified
Opt-in for
PTGX alerts

from News Quantified